Something went wrong with the connection!

Non-Muscle Invasive Bladder Cancer Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Non-Muscle Invasive Bladder Cancer Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 28
21:01 2020
Non-Muscle Invasive Bladder Cancer Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer (NMIBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Non-Muscle Invasive Bladder Cancer (NMIBC) is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.

 

Non-Muscle Invasive Bladder Cancer Market Insight

The market size of Non-Muscle Invasive Bladder Cancer in 7MM in 2017 was USD 1,454 Million  

 

NMIBC remains a very challenging disease to treat with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.

 

The current treatment regimen include surgery, intravesical immunotherapy (BCG) and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy which is the gold standard treatment for reducing tumor recurrence rates and preventing subsequent stage progression. Stage 0 bladder cancer is most often treated with TURBT with fulguration followed by intravesical therapy within 24 h. Sometimes no further treatment is needed. Cystoscopy is then done every 3–6 months to watch for signs that cancer has come back.

In addition to this, there is only one approved drug for the treatment of NMIBC namely Keytruda (pembrolizumab) which is approved for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

There are two types of intravesical therapy, namely immunotherapy and chemotherapy. BCG is the most common intravesical immunotherapy for treating early-stage bladder cancer. It is used to help keep cancer from growing, prevents it from relapse. BCG is a germ that is related to the one that causes tuberculosis (TB), but it does not usually cause serious disease.

Non-Muscle Invasive Bladder Cancer Market Drivers

  • Imminent Launches
  • Upsurge in Research and Development
  • Enriched Understanding
  • Increased Incidence

Non-Muscle Invasive Bladder Cancer Market Barriers

  • High Cost of Therapy
  • Expression Heterogeneity
  • Lack of Approved Therapies

Request for sample pages
Table of contents

1. Key Insights

2. Executive Summary of Non-Muscle Invasive Bladder Cancer (NMIBC)

3. Competitive Intelligence Analysis for Non-Muscle Invasive Bladder Cancer (NMIBC)

4. Non-Muscle Invasive Bladder Cancer (NMIBC): Market Overview at a Glance

4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Share (%) Distribution in 2017

4.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Share (%) Distribution in 2030

5. Non-Muscle Invasive Bladder Cancer (NMIBC): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment and Management

8.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Non-Muscle Invasive Bladder Cancer (NMIBC): Seven Major Market Analysis

13.1. Key Findings

13.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size in 7MM

13.3. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in the United States

15.1.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Germany

15.3.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in France

15.4.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Italy

15.5.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Spain

15.6.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in the United Kingdom

15.7.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Non-Muscle Invasive Bladder Cancer (NMIBC) Total Market Size in Japan

15.8.3. Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

September 2020
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  

Categories